Ciprofloxacin Lactate Sodium Chloride Injection

It has a broad-spectrum antibacterial effect, especially against aerobic Gram-negative rods. It has good antibacterial activity in vitro against the following bacteria: Most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, etc. Enterobacter, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing influenza bacilli and Moraxella. It has antibacterial activity against Pseudomonas aeruginosa It has antibacterial activity against most strains of Pseudomonas. It has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus, and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, and Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. It has poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase to inhibit DNA synthesis and replication, leading to bacterial death.

The main ingredient of this product is ciprofloxacin lactate.

This product is a colorless or almost colorless clear liquid.

For use in cases caused by sensitive bacteria: 1. Urinary and reproductive system infections, including simple and complicated urinary tract infections, bacterial prostatitis, urethritis or cervicitis caused by Neisseria gonorrhoeae (including those caused by enzyme-producing strains). 2. Respiratory tract infections, including acute onset of bronchial infection and lung infection caused by sensitive Gram-negative bacilli. 3. Gastrointestinal tract infections caused by Shigella, Salmonella, enterotoxigenic Escherichia coli, Aeromonas hydrophila, Vibrio parahaemolyticus, etc. 4. Typhoid fever. 5. Bone and joint infections. 6. Skin and soft tissue infections. 7. Systemic infections such as sepsis.

This product is for intravenous drip administration. For any patient, the dosage should be determined according to the degree and nature of the infection, the sensitivity of the pathogen, the patient's body resistance, and liver and kidney function. The general dosage for adults is 0.1-0.2g per day, intravenously dripped once every 12 hours, and the drip time for each 0.2g is at least 30 minutes. For severe infection or Pseudomonas aeruginosa infection, the dose can be increased to 0.4g per day, 2-3 times a day. The course of treatment depends on the degree of infection. Usually the treatment lasts for 7-14 days, and it should be continued for at least 2 days after the symptoms of infection disappear. Urinary tract infection: 5-7 days for acute simple lower urinary tract infection; 7-14 days for complicated urinary tract infection, pneumonia and skin and soft tissue infection: 7-14 days; intestinal infection: 5-7 days; bone and joint infection: 4-6 weeks or longer; typhoid fever: 10-14 days.

1 Gastrointestinal reactions are common and may manifest as abdominal discomfort or pain, diarrhea, nausea or vomiting. 2 Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. 3 Allergic reactions: rash, skin itching, occasionally exudative erythema multiforme and angioedema. A few patients have photosensitivity reactions. 4 Occasionally, (1) epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, tremors. (2) interstitial nephritis manifestations such as hematuria, fever, and rash. (3) phlebitis. (4) crystalluria, more common when used in high doses. (5) joint pain. 5 A small number of patients may experience elevated serum aminotransferase, elevated blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

Patients with a history of allergy to this product or any fluoroquinolone are contraindicated.

1 Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2 When this product is used in combination with theophylline, competitive inhibition of the cytochrome P450 binding site may lead to a significant reduction in the liver clearance of theophylline, a prolonged blood elimination half-life, an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. Therefore, theophylline blood drug concentration should be measured and the dose adjusted when used in combination. 3 Cyclosporine combined with this product can increase the blood drug concentration of the former. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4 When this product is used in combination with the anticoagulant warfarin, it can enhance the anticoagulant effect of the latter. When used in combination, the patient's prothrombin time should be closely monitored. 5 Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, toxicity may occur due to the increased blood concentration of this product. 6. This product interferes with the metabolism of caffeine, resulting in reduced caffeine clearance, prolonged blood elimination half-life, and possible central nervous system toxicity.

Keep in a light-proof and airtight container.

100ml: Ciprofloxacin 0.2g and sodium chloride 0.9g